paroxetine has been researched along with reboxetine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Avenoso, A; Facciolà, G; Scordo, MG; Spina, E | 1 |
| Carpentier, C; Costentin, J; Leroux-Nicollet, I; Naudon, L; Vilpoux, C | 1 |
| Ferguson, JM; Schwartz, GE; Wesnes, KA | 1 |
| Arnone, D; Hansen, L; Kerr, JS | 1 |
| Frazer, A; Gould, GG; Morilak, DA; Pardon, MC | 1 |
| Bellodi, L; Bertani, A; Caldirola, D; Di Pasquale, D; Migliarese, G; Perna, G | 1 |
| Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
| Bellodi, L; Bertani, A; Caldirola, D; Cucchi, M; Di Pasquale, D; Migliarese, G; Perna, G | 1 |
| Carey, GJ; Gold, LH; Nielsen, DM | 1 |
| Baldwin, D; Bridgman, K; Buis, C | 1 |
| Balogh, A; Eberhardt, AM; Härtter, S; Hiemke, C; Kirsch, M; Kuhn, UD; Maurer, I; Merkel, U; Volz, HP; Wenda, B | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Bayindirli, D; Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M; Vural, G | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Barbato, A; Bortolotti, A; D'Avanzo, B; Fortino, I; Franchi, C; Merlino, L; Nobili, A; Parabiaghi, A; Tettamanti, M | 1 |
| Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N | 1 |
| Buoli, M; Cahn, W; Serati, M | 1 |
| Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A | 1 |
4 review(s) available for paroxetine and reboxetine
| Article | Year |
|---|---|
Citalopram versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Humans; Morpholines; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Central Nervous System Stimulants; Desipramine; Dopamine Agents; Droxidopa; Drug Combinations; Duloxetine Hydrochloride; Guanfacine; Histamine Agents; Humans; Lisdexamfetamine Dimesylate; Lithium Compounds; Lobeline; Mecamylamine; Memantine; Modafinil; Morpholines; Nicotinic Agonists; Nicotinic Antagonists; Nomifensine; Paroxetine; Pyridines; Pyridoxine; Pyrrolidonecarboxylic Acid; Quinazolinones; Reboxetine; Venlafaxine Hydrochloride; Wakefulness-Promoting Agents | 2016 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipramine; Clonazepam; Desipramine; Diazepam; Fluoxetine; Humans; Network Meta-Analysis; Panic Disorder; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2023 |
7 trial(s) available for paroxetine and reboxetine
| Article | Year |
|---|---|
No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Drug Interactions; Enzyme Inhibitors; Female; Humans; Isoenzymes; Male; Morpholines; Paroxetine; Phenotype; Reboxetine; Time Factors | 1999 |
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study.
Topics: Adolescent; Adult; Analysis of Variance; Bronchial Hyperreactivity; Carbon Dioxide; Chi-Square Distribution; Double-Blind Method; Female; Humans; Male; Morpholines; Panic Disorder; Paroxetine; Reboxetine; Statistics, Nonparametric | 2004 |
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
Topics: Adrenergic Uptake Inhibitors; Adult; Female; Humans; Male; Morpholines; Panic Disorder; Paroxetine; Psychometrics; Reboxetine; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 2004 |
Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Sexual Behavior; Sexual Dysfunctions, Psychological | 2006 |
Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Genotype; Humans; Male; Mixed Function Oxygenases; Morpholines; Mutation; Paroxetine; Phenotype; Reboxetine; Reference Values; Selective Serotonin Reuptake Inhibitors | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
10 other study(ies) available for paroxetine and reboxetine
| Article | Year |
|---|---|
Differential effects of chronic antidepressant treatments on micro- and delta-opioid receptors in rat brain.
Topics: Animals; Antidepressive Agents; Autoradiography; Binding Sites; Brain; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Injections, Intraperitoneal; Male; Moclobemide; Morpholines; Paroxetine; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Opioid, delta; Receptors, Opioid, mu; Time Factors | 2002 |
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dystonic Disorders; Electroconvulsive Therapy; Humans; Male; Morpholines; Olanzapine; Paroxetine; Pirenzepine; Reboxetine | 2002 |
Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Autoradiography; Binding Sites; Brain; Brain Mapping; Carrier Proteins; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Interactions; Idazoxan; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Symporters; Time Factors; Tissue Distribution; Tyrosine 3-Monooxygenase | 2003 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines | 2004 |
[Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Attention; Brain; Depressive Disorder; Humans; Morpholines; Motivation; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Morpholines; Parkinson Disease, Secondary; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2010 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology; Practice Patterns, Physicians'; Publication Bias; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |